Novo CEO calls Wegovy problems "a perfect storm," will not move production in-house
A productions halt at a US-based subcontractor has been a fly in the ointment for the launch of Novo’s obesity drug Wegovy. However, CEO Lars Fruergaard Jørgensen isn’t considering bringing more of the production chain in-house in the future.
by ANDREAS LØNSTRUP, translated by daniel pedersen
Serious production problems at one of Novo Nordisk’s subcontractors have meant that the Danish pharmaceutical company won’t be able to meet the full demand of its newly launched obesity treatment, Wegovy.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Catalent behind Novo Nordisk's supply issues, says media
For subscribers
